A noticeable reduction in BrdU incorporation is evident in TPC1 cells treated with BI-D1870 (15.83%) compared to untreated cells (50.24%) (Figure 5B, supplementary Figure S5B) demonstrating that inhibition of p90RSK leads to a significant reduction in the replicative potential of TPC1 tumor cells, probably due to the increase in p21. This evidence concerns the gene RPS6KA1 and neoplasm.